Response Adaptive Radiotherapy Following Immunotherapy-based Induction for Non-HPV Related HNSCC - Trial NCT06345287
Access comprehensive clinical trial information for NCT06345287 through Pure Global AI's free database. This Phase 2 trial is sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences and is currently Recruiting. The study focuses on Head and Neck Cancer. Target enrollment is 133 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Timeline & Enrollment
Phase 2
Jan 01, 2024
Dec 31, 2026
Primary Outcome
Progression-free survival
Summary
The aim of this study is to develop an adaptive radiation therapy plan for locally advanced
 head and neck squamous cell carcinoma receiving induction therapy containing immunotherapy
 and chemotherapy. The therapy plan is based on clinical remission, in order to reduce
 treatment-related toxic side effects without sacrificing clinical efficacy and improve the
 quality of life of patients.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06345287
Non-Device Trial